Eurostat’s snapshot published on 2 October compares two different parts of health-system capacity: administrative programme participation in breast screening and the number of mammography machines relative to population. For the first indicator, the reference year is 2024. Denmark recorded 82.1% of eligible women in the published age group, Sweden 82.0%, Finland 81.6%, Slovenia 77.8% and Ireland 71.2%. At the lower end of countries with values, Hungary recorded 27.2%, Cyprus 29.2%, Poland 33.8%, Latvia 38.2% and Austria 41.3%. These figures describe programme records; they do not establish why countries differ, nor do they measure an individual woman’s health or outcome.

The denominator matters. Eurostat says the rate is the share of women aged 50 to 69 who had mammography during the previous two years, or according to the screening interval recommended nationally, among women eligible for an organised programme. This is not a population-wide estimate for every woman in that age range. National rules and collection systems vary, and the source notes that some changes may have occurred during the period. Sweden’s programme covers ages 40 to 74, a wider range than the headline comparison. Bulgaria and Romania have no national breast-cancer screening programme and therefore no comparable programme rate; Greece’s rate is also unavailable. In other countries, screening may take place through general practitioners or programme data may not be collectable. Missing observations must not be read as zero participation.

The change since 2019 is reported in percentage points, which is an absolute difference between two percentages, not a relative growth rate. Among countries with available data, nine increased. Slovakia had the largest rise, 12.5 percentage points, followed by Croatia at 10.0 and Estonia at 9.9. Sweden and Finland were unchanged. The other 11 countries recorded declines, ranging from 0.4 percentage points in Ireland to 21.8 in Malta. These comparisons describe the difference between reported endpoints; the release does not provide a full annual series here, so they should not be turned into a year-by-year trajectory or explanation.

A separate indicator concerns machines designed exclusively for mammograms, measured per 100,000 inhabitants. In 2024, Greece reported 7.6 units and Cyprus 6.9, followed by Italy at 3.7. Poland, Czechia, Sweden and Romania were at the low end, each with 1.1. Compared with 2019, density rose in ten countries, most in Cyprus by 1.3 units per 100,000 inhabitants; it fell in four, including Sweden by 0.8 and Malta by 0.7, while six were unchanged. Equipment density uses the whole population as denominator, unlike programme participation, whose denominator is eligible women. It is not a direct measure of appointment availability, geographic access, machine utilisation, waiting time or quality of care. Data for Germany, Ireland, France, Hungary, the Netherlands and Portugal are unavailable for both comparison years.

The figures come from Eurostat datasets hlth_ps_prev and hlth_rs_medim, which the statistical office last updated on 13 July 2026; the news snapshot was released on 2 October. The first dataset contains programme-based preventive screening rates, while the second records medical imaging devices. Their differing concepts and gaps limit cross-country interpretation. Neither indicator alone establishes screening effectiveness, cancer incidence, mortality, or the reason behind a trend. The data are useful for describing reported programme reach and equipment density, with those boundaries visible. They are not personal medical guidance, and readers should not infer an individual screening recommendation from a country comparison.